bs-19491R **[Primary Antibody]**

NT5DC2 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 64943 **SWISS:** Q9H857

Target: NT5DC2

Immunogen: KLH conjugated synthetic peptide derived from human NT5DC2: 251-350/520.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: NT5DC2 (5'-Nucleotidase Domain Containing 2) is a Protein Coding gene. GO annotations related to this gene include hydrolase activity and 5-nucleotidase activity. An important paralog of this gene is NT5DC3.

Applications: **WB** (1:500-2000)
IHC-P (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)

Reactivity: Human, Rat (predicted: Mouse, Rabbit, Pig, Sheep, Dog, Horse)

Predicted MW.: 61 kDa

Subcellular Location: Cytoplasm

VALIDATION IMAGES



Sample: HT1080(Human) Cell Lysate at 30 ug Primary: Anti-NT5DC2 (bs-19491R) at 1/500 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 61 kD Observed band size: 61 kD



Paraformaldehyde-fixed, paraffin embedded (rat stomach tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (NT5DC2) Polyclonal Antibody, Unconjugated (bs-19491R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.

SELECTED CITATIONS

- **[IF=5]** Zhen Huang. et al. Low NT5DC2 expression predicts favorable prognosis and suppresses soft tissue sarcoma progression via ECM-receptor interaction pathway. TRANSL ONCOL. 2024 Jun;44:101937 IHC ;Human. 38547613
- **[IF=3.2]** Zhang Xiaobo. et al. circ_0046599 Promotes HCC Progression by Competing with miR-1322 to Enhance NT5DC2 Expression. J CANCER. 2025 Mar;16(7):2275-2288 WB,IHC ;Human. 40302808